Brain Impact Factor

The first signal is status. Brain is operating in the flagship neurology tier, not in the broad middle of neuroscience publishing.

The second signal is durability. The five-year JIF of 12.8 sits above the current JIF, and the cited half-life of 9.9 years is long. That means the journal's best papers tend to remain useful well after the short-term citation window fades.

The third signal is normalized strength. The JCI of 3.38 is very strong. That matters because clinical neurology and neuroscience have varied citation behavior across imaging, cognitive neurology, movement disorders, neurodegeneration, and translational model work. Brain is clearly outperforming its category baseline after normalization.

The fourth signal is cleanliness. The JIF without self-cites is 11.4, almost the same as the headline JIF. That is another reason to treat the metric as durable and credible.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 8.29 in 2023 to 9.05 in 2024. The larger pattern is a stable high-impact neurology journal that has strengthened again after a flatter middle period.

That fits the official Oxford page too. Brain still presents itself as a home for landmark papers in clinical neurology and translational neuroscience, and the metrics support that positioning.

The most common mistake is to see 11.7 and assume Brain works like a broad elite neuroscience journal.

That misses the real screen. Brain may publish mechanistic and translational neuroscience, but it is still fundamentally a neurology journal. Papers often miss here when they are:

• biologically strong but too basic
• clinically relevant but not mechanistically deep enough
• technically rigorous but too narrow in neurological consequence

The number says the journal is elite. It does not say that any strong neuroscience paper has the right ownership here.

In our pre-submission review work with manuscripts targeting Brain, three patterns generate the most consistent desk-rejection outcomes.

The science is strong, but the neurological consequence is still too implied. We often see excellent mechanistic work where the disease or clinical implication is more hoped-for than convincingly shown.

The study is clinically interesting, but the paper lacks enough mechanistic depth. Brain usually wants more than a useful observation if the biological explanation remains too thin.

The manuscript feels like excellent neuroscience rather than flagship neurology. That difference sounds subtle, but editors make it quickly.

If that sounds familiar, a Brain submission readiness review is usually more useful than another round of cosmetic editing.

The official Oxford Academic about page adds a useful non-JCR signal. It currently lists:

• 2024 Impact Factor 11.7
• 2024 5-Year Impact Factor 12.8
• Clinical Neurology rank by impact factor: 5/286
• 2024 Cited Half-Life 9.9 years
• 2025 median days from submission to first decision: 6 days

The exact rank denominator on the live Oxford page is slightly different from the current JCR row in this repo, so I am using the internal JCR source of truth for the page claims. But the broader message is consistent: Brain combines flagship status with fast editorial triage.

That matters because it changes how authors should read the metric. Brain is not only high impact. It is high impact and editorially impatient.

The impact factor does not tell you whether the paper is neurologically important enough, whether the translational bridge is convincing enough, or whether the better home is a broader neuroscience journal.

That is the main trap. The metric can tempt authors to overread prestige while underrating fit.